注册送68:扫码存眷科兴官方微旌旗灯号“疫苗之益”

Our History
2021

The COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac® was approved for Conditional marketing authorization or emergency use approval of the COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac®, granted in dozens of countries including China, Chile, Turkey, Brazil, and Indonesia

2020

Commercially launched the live attenuated Varicella Live Vaccine, Live


Commercially launched the Influenza Inactivated Vaccine (Split Virion), Inactivated, Quadrivalent 


Commercially launched the 23-valent Pneumococcal Polysaccharide Vaccine

Initiated a project named, "Anti COVID-19 Action" , to develop an inactivated COVID-19 vaccine, 

CoronaVac®, which was. To be the first one batch of COVID-19 vaccines in China to be approved for emergency use


The company's fourth production site base - Beijing Daxing Campus- was put into use 


Sinovac (Singapore) Ltd. was incorporationincorporated


2017
MetInfo enterprise content manager system | MetInfo CMS

Sinovac’s Inactivated Hepatitis A vaccine, Healive®, passed the pre-qualification assessment by the WHO, making it’s the only hepatitis A vaccine in China that passed the pre-qualification assessment by WHOto reach this milestone.

2016
MetInfo enterprise content manager system | MetInfo CMSMetInfo enterprise content manager system | MetInfo CMS

Commercially launched the world's first class I1 new drug for preventative biological products - Enterovirus Type 71 Inactivated Vaccine (Vero Cell) , Inactivated, Inlive®

2012
MetInfo enterprise content manager system | MetInfo CMS

Commercially launched an live attenuated Mumps live Vaccine

2010
MetInfo enterprise content manager system | MetInfo CMS

Sinovac (Dalian) Vaccine Technology Co., Ltd. was incorporatedincorporatedfounded;

MetInfo enterprise content manager system | MetInfo CMS

Construction began on tthe new Changping new vaccine industrial base

2009
MetInfo enterprise content manager system | MetInfo CMS

The world’s first H1N1 Influenza A Inactivated Vaccine (Split Virion), Inactivated, Panfu.1®, was approved to producefor production and started mass ive vaccination was started started.

MetInfo enterprise content manager system | MetInfo CMS

Sinovac stepped into the international market, with itsSinovac international market initated; Healive® vaccine exported to Mongolia;  and the and Anflu®, vaccine exported to the Philippines;

MetInfo enterprise content manager system | MetInfo CMS

Sinovac Life Sciences Sciences Co., ., Ltd. was incorporated;

Sinovac Holdings was moved to the NASDAQ Global Select Market

2008
MetInfo enterprise content manager system | MetInfo CMS

China’s first Pandemic Influenza Vaccine (Inactivated, Adjuvanted), PanFlu®, was approved to be produced for government stockpiling.

Sinovac Biotech (Hong Kong) Ltd. was incorporated.


2007
MetInfo enterprise content manager system | MetInfo CMS

Sinovac became the first manufacturer enterprise from a developing country to join the IFPMA.

2006
MetInfo enterprise content manager system | MetInfo CMS

Commercially Launched launched an Influenza Inactivated Vaccine (Split Virion), Inactivated, Anflu®

MetInfo enterprise content manager system | MetInfo CMS
2005
MetInfo enterprise content manager system | MetInfo CMSMetInfo enterprise content manager system | MetInfo CMS

Commercially Launched launched China's first and the world's second Hepatitis A and Hepatitis B Combined Vaccine, Bilive®

2004
MetInfo enterprise content manager system | MetInfo CMS

Resulting unblindingRevealed The of the results of the phase I clinical research trailsresult study onf the world's of the first SARS inactivated Vvaccine, inactivated  is unblinded

MetInfo enterprise content manager system | MetInfo CMS

Initiation ofed the development research of on a pandemic influenza vaccine to protect against human infection from the highly pathogenic avian influenza virus (H5N1)

Sinovac shares werewas listed on the American Stock Exchange (AMEX)


2003
MetInfo enterprise content manager system | MetInfo CMS

Initiation ofed the development of an inactivated SARS Vaccine R&D program , and completed ion of pre-clinical studyresearch

Sinovac was listed in US


2002
MetInfo enterprise content manager system | MetInfo CMSMetInfo enterprise content manager system | MetInfo CMSMetInfo enterprise content manager system | MetInfo CMS

Commercially launched China’s first inactivated hepatitis A vaccine, Healive®, was commercially launched


2001
MetInfo enterprise content manager system | MetInfo CMS

Sinovac Biotech Co., Ltd. incorporatedwas founded


1999
MetInfo enterprise content manager system | MetInfo CMSMetInfo enterprise content manager system | MetInfo CMS

A “new drug certificate” was obtained for tTheIts Iiinactivated Hhhepatitis A vaccine was certificated as a new drug


1996
MetInfo enterprise content manager system | MetInfo CMS

Cooperated with the National Institute for the Control of Pharmaceutical and Biological Products to initiate the development of an inactivated Hepatitis A vaccine


1987
MetInfo enterprise content manager system | MetInfo CMS

Developed China’s first Hepatitis A enzyme-linked diagnostic reagent

1985
MetInfo enterprise content manager system | MetInfo CMSMetInfo enterprise content manager system | MetInfo CMS

Successfully isolated the TZ84 strain of the hepatitis A virus

1982

Conducted an investigation into endemic areas with endemic hepatitis A